Intrauterine Growth Restriction (IUGR) as a Potential Target for Transamniotic Stem Cell Therapy
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Feb 2022 · 1 min read
In brief
In brief
Experimental study evaluating transamniotic mesenchymal stem cell therapy (TRASCET) as a potential treatment for intrauterine growth restriction in a hypoxia-induced animal model. Researchers compared outcomes between untreated IUGR fetuses and those receiving intra-amniotic injections of native or cytokine-primed amniotic fluid-derived stem cells.
Written by the GCMD Library team from the article.
Background
We sought to determine whether intrauterine growth restriction (IUGR) could be a target for mesenchymal stem cell (MSC)-based transamniotic stem cell therapy (TRASCET).
Methods
Pregnant dams subjected to hypoxia (10.5% O2) cycles had their fetuses divided into four groups: untreated (n=24) and three groups receiving volume-matched intra-amniotic injections of either saline (sham; n=16), or suspensions of luciferase-labeled, syngeneic amniotic fluid-derived MSCs that were either native (TRASCET-unprimed; n=29), or primed by exposure to IFNγ and IL-1β (TRASCET-primed; n=31). Normal fetuses served as additional controls (n=22). Multiple analyses were performed at term.
Results
Compared to normal, fetal weights were significantly decreased in all hypoxia groups (p=0.002 to